Investigational drug · Phase 2
Denikitug
Also called: GS-1811, DEN
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Microsatellite Stable Colorectal Cancer, HER2-negative, Gastroesophageal Junction.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Denikitug"
First trial start
2026
May 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Denikitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Microsatellite Stable Colorectal Cancer
- HER2-negative
- Gastroesophageal Junction
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Denikitug" as an intervention, largest first.
- Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05007782 · 304 participants · Start Aug 18, 2021 · Primary completion Dec 2028
Drug: Denikitug; Zimberelimab · For: Advanced Solid Tumor
Sites: La Jolla, California; Palo Alto, California; New Haven, Connecticut · 25 sites in all
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07527858 · 170 participants (planned) · Start May 19, 2026 · Primary completion Dec 2028
Drug: Denikitug; Nivolumab and 2 more · For: Advanced Microsatellite Stable Colorectal Cancer
Sites: North Haven, Connecticut; Boston, Massachusetts; St Louis, Missouri · 15 sites in all
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07546812 · 120 participants (planned) · Start Aug 7, 2026 · Primary completion Jan 2030
Drug: Denikitug; Nivolumab and 2 more · For: HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma and 1 more
Sites: Boston, Massachusetts; Albany, New York; New York, New York · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The social implications of classroom seats: replicating and extending previous findings on seating arrangements and peer status.
Vandemeulebroucke DN, van den Berg YHM, Hoekstra NAH, et al. · J Exp Child Psychol 2027
- From patient to partner: Bridging the divide from laboratory to patient through a "Dragons' Den" style model of co-creation in cancer research.
Job A, Agass B, Coles CE, et al. · Tech Innov Patient Support Radiat Oncol 2026
- Nrf2 exerts an unfavorable role in chemical hepatotoxicity in mice by maintaining CYP2E1 protein stability.
Wu R, Xia Y, Cui M, et al. · Chem Biol Interact 2026
- MEX3A mediates DHRS3 instability to relieve G0/G1 arrest and facilitate hepatocellular carcinoma tumorigenesis and progression.
Li W, Mo S, Zhang W, et al. · Biochem Pharmacol 2026
- Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma.
Boehmler DJ, Baron RJ, Brain JA, et al. · Hepatology 2026
- Hepatitis B splicing-generated protein prevents tumor initiation but shapes a pro-tumor immune microenvironment in established HCC.
Lekbaby B, Sotty J, Nguyen Dang H, et al. · Hepatol Int 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.